Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men

BJU International

Volumn 97, Issue 6, 2006, Pages 1190-1193

  Fukagai, Takashi ^a,b   Namiki, Thomas S ^b   Carlile, Robert G ^b   Yoshida, Hideki ^a   Namiki, Mikio ^c  

^a SHOWA UNIVERSITY   (Japan)

^b UNIVERSITY OF HAWAII   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Clinical outcome; Hormonal therapy; Prostate cancer; Racial differences

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASIAN; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; GLEASON SCORE; HUMAN; JAPAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RACE DIFFERENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GONADOTROPIN-RELEASING HORMONE; HAWAII; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33745194354     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06201.x     Document Type: Article

References (20)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55: 10 30
2. Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T. Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer 1991 67: 746 63
3. Zaridze DG, Boyle P, Smans M. International trends in prostatic cancer. Int J Cancer 1984 33: 223 30
4. Ross RK, Bernstein L, Lobo RA et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992 339: 887 9
5. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000 92: 2009 17
6. Eisenberger MA, Crawford ED, Wolf M et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994 21: 613 9
7. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001 93: 219 25
8. Pienta KJ, Demers R, Hoff M, Kau TY, Montie JE, Severson RK. Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology 1995 45: 93 102
9. McLeod DG, Schellhammer PF, Vogelzang NJ et al. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate 1999 40: 218 24
10. Koff SG, Connelly RR, Bauer JJ, McLeod DG, Moul JW. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. Prostate Cancer Prostatic Dis 2002 5: 152 8
11. Young JL Ries LG, Pollack ES. Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 1984 73: 341 52
12. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355: 1491 8
13. Shiraishi T, Atsumi S, Yatani R. Comparative study of prostatic carcinoma bone metastasis among Japanese in Japan and Japanese Americans and whites in Hawaii. Adv Exp Med Biol 1992 324: 7 16
14. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996 29: 117 34
15. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene in linkage disequilibrium in men with prostate cancer. Cancer Res 1995 55: 1937 40
16. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999 81: 672 6
17. Suzuki H, Akakura K, Komiya A et al. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 2002 51: 219 24
18. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999 53: 378 80
19. Jin B, Beilin J, Zajac J, Handelsman DJ. Androgen receptor gene polymorphism and zonal volumes in Australian and Chinese men. J Androl 2000 21: 91 8
20. Hsing AW, Gao YT, Wu G et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000 60: 5111 6